A corporate venture capital fund invests globally in technologies with potential to impact mortality rates at scale by improving healthcare quality and outcomes to support the corporation’s goal of helping save 1M lives annually by 2030. This fund prioritizes technologies that address acute, time-critical conditions and makes investments internationally. The firm will invest up to $5M USD for their first check with capital reserved to follow on. The firm currently has 12 portfolio companies and is actively deploying capital. 
 
The firm invests solely in medical devices, diagnostics, and digital health. The fund does not invest in therapeutics, biotech, pharma, and CROs. The fund looks at acute, time-critical areas of healthcare and is interested in solutions that support prevention, earlier identification and intervention, and improved therapeutics for these conditions. Key areas of focus include, but are not limited to cardiovascular care, sepsis, stroke, trauma and surgery, maternal and neonatal care, emergency medicine, and healthcare education & training. 
 
The firm can act both as a lead and co-investor. The firm needs to see committed and full-time teams with demonstrated product market fit. The fund invests in pre- and post- FDA approval companies, but companies should have an MVP and licensed IP where relevant. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An early-stage venture capital firm was founded in 2010 and based in the US. The firm is a generalist fund, looking to expand its footprint in life sciences, specifically data, diagnostics, and therapeutics in oncology.  The firm focuses on Pre-Seed, Seed, and Series A investments. Typical check size ranges from $500k-5M USD, leading rounds. The firm focuses on companies in the US. 
 
The firm invests in data, diagnostics and therapeutics, with a strong preference in oncology. The firm was one of the first institutional investors in Tempus, an AI-driven data and diagnostics platform, and Pathos, an AI-driven clinical stage therapeutics platform in oncology.  Within therapeutics, companies should be pre-Phase II and for data and diagnostics companies, in-development stages. 
 
The firm does not require to take a board or observer seat but often will. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm founded and headquartered in Taiwan is overall focused on investing in biotech and tech-related companies such as AI, biotech, medical device, pharma, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Central Eastern Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S. 
 
The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on are chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data. 
 
The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm specialized in life sciences and medical technology, managing both RMB and USD funds with a total size of $1.5B, is operated by a professional team with diversified and profound industry backgrounds, having made over 90 investments with high growth potential since 2014. Typical Allocations Size of the firm’s RMB fund is 30MM-150MM in RMB, and up to 200MM in RMB; for the USD fund, the firm invests $5-10MM+ on average, and up to $20MM. 
 
The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. Especially, the firm is interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. The firm is not interested in small molecules nor antibodies for now. 
 
The firm prefers companies that are tech-driven, commercially viable and are able to solve the real problem. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment firm headquartered in the US focuses on investing in public and private healthcare companies. In terms of early-stage companies, the firm is stage-agnostic with check sizes ranging from $10M-40M USD at the Series A round. The firm has a heavy bias for U.S.-based companies but may look at the EU. 
 
The firm is stage-, modality-, and indication-agnostic. For therapeutics, interests include genetically driven assets and novel biology/target/MoA. The firm typically does not invest in companies, for example, vaccine or immune-oncology companies unless there is clinical or human data. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment bank based in the US actively seeks new investment opportunities. The firm does not act as a traditional investment bank, as they participate in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public market. The firm generally does not look at digital health. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes their sister company to further analyze company technologies and IPs. The firm can fund from $5M-12M USD from Seed to Series A rounds with preference in US-based companies, though open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 
The firm works closely with companies and founder and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.